Arecor Ltd (“the Company”), the leading formulation technology company, focussed on developing superior biopharmaceuticals via the innovative reformulation of proteins and peptides to improve the treatment of diabetes and other conditions, is pleased to announce that a global pharmaceutical and healthcare company, has exercised its license option to Arecor’s proprietary formulation technology, to develop differentiated biosimilar products.
For more details: please visit http://www.arecor.com/news-events/arecor-announces-license-agreement-global-pharmace/
